Table 1 TAR–adjusted CF-AE rates in LL3, LL1, and a pooled analysis of 3865 patients
From: Cardiac safety of afatinib: a review of data from clinical trials
LL3 | Afatinib (40 mg/day) n = 229 | Chemotherapy n = 111 |
TAR (mo) | 11.5 | 3.7 |
TAR-adjusted CF-AE rate (events/100 patient-years) | 2.28 | 2.92 |
HR (95 % CI) | 1.18 (0.12, 11.39; p = 0.8870) | |
LL1 | Afatinib (50 mg/day) n = 390 | Placebo n = 195 |
TAR (mo) | 5.1 | 2.8 |
TAR-adjusted CF-AE rate (events/100 patient-years) | 2.40 | 2.23 |
HR (95 % CI) | 1.32 (0.14, 12.50; p = 0.8086) | |
Pooled | Afatinib n = 3865 | |
TAR (mo) | 5.7 | |
TAR-adjusted CF-AE rate (events/100 patient-years) | 2.88 | |